2. Search Result
Search Result
Results for "

Influenza A

" in MedChemExpress (MCE) Product Catalog:

539

Inhibitors & Agonists

4

Screening Libraries

4

Fluorescent Dyes

5

Biochemical Assay Reagents

48

Peptides

17

Inhibitory Antibodies

116

Natural
Products

349

Recombinant Proteins

40

Isotope-Labeled Compounds

1

Antibodies

2

Click Chemistry

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W019823
    4-MUNANA
    2 Publications Verification

    		 Fluorescent Dye Infection Neurological Disease
    4-MUNANA is a substrate of influenza virus neuraminidase (NA) with high selectivity and irreversible reaction. In the enzymatic reaction, 4-MUNANA is hydrolyzed by NA to generate fluorescent 4-methylumbelliferone (4-MU). By detecting the fluorescence intensity of 4-MU, quantitative analysis of NA activity can be achieved. 4-MUNANA can be used in influenza-related research, such as screening NA inhibitors, developing new anti-influenza drugs, and studying the infection mechanism of influenza viruses .
    4-MUNANA
  • HY-N0035
    Arctigenin
    10+ Cited Publications

    (-)-Arctigenin

    		 MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin
  • HY-145586
    Onradivir

    ZSP1273

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection .
    Onradivir
  • HY-B1589A
    Carbinoxamine maleate salt
    1 Publications Verification

    		 Histamine Receptor Influenza Virus Infection Inflammation/Immunology
    Carbinoxamine maleate salt is a blood-brain barrier-permeable histamine H1 receptor antagonist. Carbinoxamine maleate salt blocks the action of histamine on H1 receptors, reducing symptoms such as sneezing, rhinitis, rhinorrhea, erythema, pruritus and urticaria. Carbinoxamine maleate salt inhibits influenza virus entry into cells via endocytosis, targets the early stage of the viral life cycle, and simultaneously reduces viral replication levels in the lungs, alleviating pathological damage and inflammatory responses in lung tissues. Carbinoxamine maleate salt can be used in research on allergic rhinitis, influenza, etc.
    Carbinoxamine maleate salt
  • HY-P991446
    MEDI-8852

    		Influenza Virus Infection
    MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    MEDI-8852
  • HY-175469
    VNT-101

    		Influenza Virus Infection
    VNT-101 is an orally active influenza A (IAV) inhibitor. VNT-101 disrupts NP-NP PPI to block NP oligomerization and destabilize the viral ribonucleoprotein (RNP) complex, with potent antiviral activity across multiple influenza A subtypes. VNT-101 exhibits EC50 values of 4-5 nM in cellular cytopathic effect (CPE) assay, 4-8 nM in neuraminidase (NA) assay, and 21-45 nM in RNP assay. VNT-101 demonstrates robust in vivo antiviral efficacy in mice infected with lethal H1N1 virus. VNT-101 can be used for the study of influenza A infection .
    VNT-101
  • HY-P99750
    Navivumab

    CT-P23

    		 Influenza Virus Infection
    Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
    Navivumab
  • HY-W011518
    2′-Deoxy-2′-fluoroguanosine
    1 Publications Verification

    		 Nucleoside Antimetabolite/Analog Influenza Virus Infection
    2′-Deoxy-2′-fluoroguanosine is a nucleoside analog and potent influenza virus inhibitor with an EC90 value of <0.35 μM against influenza A and B viruses. 2′-Deoxy-2′-fluoroguanosine inhibits influenza virus replication in the upper respiratory tract, thereby ameliorating fever and nasal inflammation .
    2′-Deoxy-2′-fluoroguanosine
  • HY-14837
    Amizon

    Enisamium iodide

    		 Influenza Virus SARS-CoV Infection
    Amizon is an orally effective antiviral and anti-inflammatory agent. Amizon inhibits influenza virus replication and restricts viral RNA synthesis. Amizon reduces the mRNA expression of COX-1, COX-2, NF-κB, TGF1β, IL-1 and IL-6, and stimulates the secretion and mRNA expression of IL-10. Amizon inhibits the oxidative activity of macrophages and possesses antioxidant and free radical-scavenging activities. Amizon is applicable to research related to influenza and acute respiratory viral infections .
    Amizon
  • HY-D0980
    Biotin-DADOO

    Biotinyl-3,6-dioxaoctanediamine; EZ-Link Amine-PEO2-Biotin

    		 Biochemical Assay Reagents Infection
    Biotin-DADOO (Biotinyl-3,6-dioxaoctanediamine; EZ-Link Amine-PEO2-Biotin) is a biotin-containing amine compound and a biotinylation reagent. As an amino component, Biotin-DADOO participates in the nucleophilic ring-opening reaction of epoxidized ω-double bonds during the synthesis of biotinylated inhibitor derivatives. Biotin-DADOO can be conjugated with carboxymethyl cellulose derivatives. Biotin-DADOO is involved in the synthesis of biotin-estradiol conjugates for enzyme immunoassays. Biotin-DADOO can be used in the research of influenza A .
    Biotin-DADOO
  • HY-B1537
    Azaribine

    2',3',5'-Tri-O-acetyl-6-azauridine

    		 Virus Protease Influenza Virus Infection Inflammation/Immunology
    Azaribine (2',3',5'-Tri-O-acetyl-6-azauridine) is a potent orotidine monophosphate decarboxylase (OMPD) inhibitor. Azaribine is an antiviral inhibitor of several RNA viruses and inhibits viral genome replication and gene transcription. Azaribine shows broad-spectrum antiviral activity (EC50=3.80 nM-1.73 μM against influenza A and B viruses; EC50=1.62 μM against ZIKV Paraiba). Azaribine, a triacetate salt of Azauridine, has the potential for psoriasis research .
    Azaribine
  • HY-165613
    Pam2Cys

    Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine

    		 Toll-like Receptor (TLR) Influenza Virus NF-κB Infection Inflammation/Immunology
    Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection .
    Pam2Cys
  • HY-158312
    UH15-38
    1 Publications Verification

    		 Necroptosis RIP kinase Influenza Virus Infection Inflammation/Immunology
    UH15-38 is a potent RIPK3 inhibitor with an IC50 value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury .
    UH15-38
  • HY-DY1034
    4-MUNANA (solution)

    		Fluorescent Dye Infection Neurological Disease
    4-MUNANA (solution) is a substrate of influenza virus neuraminidase (NA) with high selectivity and irreversible reaction. In the enzymatic reaction, 4-MUNANA is hydrolyzed by NA to generate fluorescent 4-methylumbelliferone (4-MU). By detecting the fluorescence intensity of 4-MU, quantitative analysis of NA activity can be achieved. 4-MUNANA can be used in influenza-related research, such as screening NA inhibitors, developing new anti-influenza drugs, and studying the infection mechanism of influenza viruses .
    Solvent and Concentration: Sterile water: 10 mM
    4-MUNANA (solution)
  • HY-P990187
    Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114)

    		MHC Influenza Virus Infection Inflammation/Immunology
    Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) does not react with I-Af, I-Ak, or I-As haplotypes. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) blocks MHC Class II and inhibit T cell generation. Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) can be used for the researches of infection and immunology, such as influenza A virus (IAV) infection .
    Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114)
  • HY-P99620
    Firivumab

    CT-P22; CT120

    		 Influenza Virus Infection
    Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
    Firivumab
  • HY-P990811
    Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65))

    		Influenza Virus Infection
    Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) is mouse-derived IgG2a κ type antibody inhibitor, targeting to influenza virus nucleoprotein. Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) reacts with influenza virus nucleoprotein (NP). Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) can induce passive immunity to influenza A virus. Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) can be used for the detections of western blot, flow cytometry and immunohistochemistry in Influenza A virus infection .
    Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65))
  • HY-P1788
    Influenza A NP(366-374) Strain A/PR/8/35

    		Influenza Virus Infection
    Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein .
    Influenza A NP(366-374) Strain A/PR/8/35
  • HY-P1749
    Influenza HA (307-319)

    		Influenza Virus Infection
    Influenza HA (307-319) is 13 amino acids 307 to 319 fragment of Influenza HA. Influenza HA is a glycoprotein found on the surface of influenza viruses .
    Influenza HA (307-319)
  • HY-121473
    Aklavin

    		Antibiotic Bacterial Fungal Parasite Infection
    Aklavin is a structural analog of Aclacinomycin A (HY-N2306) produced by Streptomyces strain A 1165. Aklavin possesses Z-DNA-inducing and stabilizing activities, along with antibiotic, anti-phage and broad-spectrum antimicrobial activities. Aklavin inhibits the proliferation of various viruses (such as influenza virus and poliovirus) and interferes with their nucleoprotein synthesis, while also exhibiting inhibitory effects on staphylococci, mycobacteria and specific fungi. Aklavin blocks phage-induced bacterial lysis by regulating host-parasite interactions. Aklavin shows specific toxicity to fertilized eggs and mice, and does not alter the splicing of the SMN2 gene .
    Aklavin
  • HY-P1837
    Influenza HA (518-526)

    		Influenza Virus HSV Infection
    Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K d to form a complex, which is then recognized by specific CD8 + T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8 + T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza .
    Influenza HA (518-526)
  • HY-143744
    Suraxavir marboxil

    GP681; Cap-dependent endonuclease-IN-3

    		 Endonuclease Influenza Virus Infection
    Suraxavir marboxil (GP681; Cap-dependent endonuclease-IN-3) is a PA subunit cap-dependent endonuclease inhibitor with antiviral activity. Suraxavir marboxil inhibits PA subunit cap-dependent endonuclease activity and inhibits influenza A and/or influenza B viral replication. Suraxavir marboxil can be used alone or in combination with other anti-influenzal agents for the prevention of influenza A and/or influenza B viral infectious diseases. Suraxavir marboxil can be used for the research of influenza A and/or influenza B viral infectious diseases .
    Suraxavir marboxil
  • HY-N12110
    SMU-CX1

    		Toll-like Receptor (TLR) SARS-CoV Infection
    SMU-CX1 is a specific TLR3 inhibitor (IC50: 0.11 μM) with IC50 ranging from 0.14-0.33 μM against multiple influenza A virus subtypes. SMU-CX1 inhibits the viral PB2 and NP proteins with an IC50 of 0.43 μM for SARS-CoV-2 activity. SMU-CX1 also inhibits inflammatory factors in host cells, including IFN-β, IP-10, and CCL-5 .
    SMU-CX1
  • HY-134922
    NS1-IN-1

    		Influenza Virus Infection
    NS1-IN-1 (compound 3) is a potent NS1 inhibitor. NS1 is a major influenza A virus virulence factor that inhibits host gene expression. NS1-IN-1 decreases viral protein levels, contributing to the reduction of virus replication. NS1-IN-1 shows antiviral activity by repressing the activity of mTORC1 in a TSC1-TSC2-dependent manner .
    NS1-IN-1
  • HY-143494
    RSV/IAV-IN-3

    		RSV Influenza Virus Infection
    RSV/IAV-IN-3 (compound 14'i) is a dual inhibitor of respiratory syncytial virus (RSV) and influenza A virus (IAV) with EC50 values of 2.92 µM and 1.90 µM,respectively. RSV/IAV-IN-3 has antiviral effect against H1N1 and H3N2 with EC50 values of 3.25 µM and 1.50 µM in MDCK cells, respectively. RSV/IAV-IN-3 significantly inhibits the activity of luciferase in a dose-dependent manner, with an EC50 of 3.89 µM. RSV/IAV-IN-3 inhibits IAV infectivity and RdRp activity. RSV/IAV-IN-3 inhibits IAV and RSV replication at the post-entry stage .
    RSV/IAV-IN-3
  • HY-123304
    MBX2546

    		Influenza Virus Infection
    MBX2546 is a influenza A virus inhibitor with the Kd values of 5.3μM and ＞ 100 μM for H1 Hemagglutinin and H3 Hemagglutinin, respectively .
    MBX2546
  • HY-W892911
    AV-5080

    		Influenza Virus Infection
    AV-5080 is an orally active neuraminidase inhibitor. AV-5080 can be used for the research of influenza A and B viruses .
    AV-5080
  • HY-131069A
    MBX2329

    		Influenza Virus Infection
    MBX2329, a potent influenza virus inhibitor, specifically inhibits hemagglutinin (HA)-mediated viral entry with HIV/HA(H5) displaying IC90 of 8.6 μM. MBX2329 inhibits a wide spectrum of influenza A viruses, which includes the 2009 pandemic influenza virus A/H1N1/2009, highly pathogenic avian influenza (HPAI) virus A/H5N1, and oseltamivir-resistant A/H1N1 strains .
    MBX2329
  • HY-N7346
    Lucidadiol

    		HSV Cholinesterase (ChE) Infection
    Lucidadiol is a natural compound isolated from Ganoderma lucidum. Lucidadiol exhibits acetylcholinesterase-inhibitory activity, with IC50 values of 31 μM. Lucidadiol shows antiviral activity against influenza virus type A and HSV type 1 .
    Lucidadiol
  • HY-N3421
    Koaburaside

    		Interleukin Related TNF Receptor Influenza Virus Infection Inflammation/Immunology Cancer
    Koaburaside is a cytoprotective and anti-inflammatory natural compound. Koaburaside shows antioxidant activity with an IC50 of 9.0 μM for DPPH-free radical scavenging assay. Koaburaside inhibits histamine release and expressions of IL-6 and TNF-α in human mast cells. Koaburaside also effectively inhibits influenza A neuraminidase .
    Koaburaside
  • HY-148202
    Influenza antiviral conjugate-1

    		HIV Infection
    Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Influenza antiviral conjugate-1
  • HY-112543
    S119-8

    		Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV) .
    S119-8
  • HY-145586A
    Onradivir monohydrate

    ZSP1273 monohydrate

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) monohydrate is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir monohydrate inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir monohydrate maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir monohydrate can be used for the research of influenza A virus infection .
    Onradivir monohydrate
  • HY-177791
    vRNPs degrader-1

    		PROTACs Influenza Virus Infection
    vRNPs degrader-1 is a potent PROTAC viral ribonucleoproteins (vRNPs) degrader. vRNPs degrader-1 shows broad-spectrum anti-influenza A viruses (IAV) activity by targeting the conserved 5′ end of viral RNA, thereby inducing proteasomal degradation of viral proteins. vRNPs degrader-1 inhibits H1N1, H9N2, and H3N2 infection in mice. vRNPs degrader-1 can be used for influenza research .
    vRNPs degrader-1
  • HY-131179
    Influenza A virus-IN-1

    		Influenza Virus Infection
    Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA .
    Influenza A virus-IN-1
  • HY-P1937
    Cyclo(-Met-Pro)

    		Influenza Virus Infection
    Cyclo(-Met-Pro) is a cyclic dipeptide consisting of the amino acids methionine and proline. Cyclo(-Met-Pro) exhibits weak inhibitory activity against the influenza A virus (H3N2) (5 mM, 2.1% inhibition), while cis-cyclo(Leu-Pro) and cis-cyclo(Phe-Pro) shows significant antiviral activity .
    Cyclo(-Met-Pro)
  • HY-P991054
    CR-8020

    		Influenza Virus Infection
    CR-8020 is a human IgG1 antibody that targets influenza A virus H3N2. CR-8020 binds to hemagglutinin (HA) of H3N2 strains with IC50s of 3.36 nM and 0.06 nM for A/Brisbane/10/2007 and A/Wyoming/3/2003, respectively. The isotype control for CR-8020 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    CR-8020
  • HY-P10593
    Influenza A NP (383-391) (HLA-B27)

    		Transmembrane Glycoprotein Influenza Virus Cancer
    Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research .
    Influenza A NP (383-391) (HLA-B27)
  • HY-N16441
    Pulvic acid

    		Endogenous Metabolite Influenza Virus Infection
    Pulvic acid (Compound 3), a butenolide, is a microbial secondary metabolite. Pulvic acid can be isolated from the marine-derived fungus Aspergillus terreus Gwq-48. Pulvic acid has significant antiviral activity with an IC50 of 29.1 μg/mL for influenza A H1N1 virus. Pulvic acid can be used for influenza virus infections research .
    Pulvic acid
  • HY-N0035R
    Arctigenin (Standard)

    (-)-Arctigenin (Standard)

    		 Reference Standards MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin (Standard)
  • HY-131059
    CBS1117

    		Influenza Virus Infection
    CBS1117 is a virus entry inhibitor with an IC50 of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process .
    CBS1117
  • HY-P5502A
    Influenza NP (311-325) TFA

    		Influenza Virus MHC Infection Inflammation/Immunology
    Influenza NP (311-325) TFA is an Influenza A nucleoprotein peptide. Influenza NP (311-325) TFA is a class II restricted epitope. Influenza NP (311-325) Influenza NP (311-325) TFA fused to OVA protein can be used for immunological response studies .
    Influenza NP (311-325) TFA
  • HY-N2216
    Polygalasaponin XXXI

    Onjisaponin F

    		 Influenza Virus Infection
    Polygalasaponin XXXI (Onjisaponin F) is an effective adjuvant for intranasal administration of influenza Influenza hemagglutinin (HA) vaccine to protect influenza virus infection .
    Polygalasaponin XXXI
  • HY-P1762
    Influenza NP (147-155)

    		Influenza Virus Infection
    Influenza NP (147-155) is a K d restricted epitope from influenza nucleoprotein .
    Influenza NP (147-155)
  • HY-170646
    Influenza A virus-IN-15

    		Influenza Virus Infection
    Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum inhibitor of influenza A viruses with acceptable cytotoxicity (IC50: 0.88-6.33 μM). Influenza A virus-IN-15 can inhibit the transcription and replication of viral RNA and is used in research for its antiviral effects against influenza A viruses (IAV) .
    Influenza A virus-IN-15
  • HY-149034
    Influenza A virus-IN-8

    S5

    		 Influenza Virus Infection Cancer
    Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
    Influenza A virus-IN-8
  • HY-143752
    Cap-dependent endonuclease-IN-8

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .
    Cap-dependent endonuclease-IN-8
  • HY-158097
    IAV-IN-2

    		Influenza Virus Infection
    IAV-IN-2 (Compound MC-22) inhibits for Influenza A Virus (IAV) through blocking the entry of IAV into host cell via clathrin-mediated endocytosis (CME) .
    IAV-IN-2
  • HY-178366
    PAC/NP-IN-1

    		Influenza Virus Infection
    PAC/NP-IN-1 (Compound 30) is a dual-target anti-influenza agent that specifically binds to nucleoprotein (NP) and the C-terminal domain of PA protein (PAc). PAC/NP-IN-1 inhibits influenza A virus A/WSN/33 (H1N1) (EC50 = 3.63 μM, IC50 = 3.08 μM). PAC/NP-IN-1 can be used for the study of influenza infection .
    PAC/NP-IN-1
  • HY-144066
    Cap-dependent endonuclease-IN-21

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
    Cap-dependent endonuclease-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: